# Hemokinin-1: The Mammalian Non-Neuronal NK1 Tachykinin
> Research Use Only (RUO). Hemokinin-1 and related tachykinin peptides are described here strictly as laboratory research reagents for in-vitro and biochemical study. Nothing below is a human, veterinary, clinical, diagnostic, or therapeutic claim, and no dosing guidance is implied. Handle as a research chemical under appropriate institutional safety practices.
Hemokinin-1 (HK-1) is a mammalian tachykinin with a distinctive identity: unlike the classic neuronal tachykinins, it is encoded by the TAC4 gene and produced predominantly in non-neuronal tissues — hematopoietic and immune cells. Functionally it behaves as an NK1 receptor agonist, the same preferred receptor as [substance P](/learn/substance-p-tachykinin-neuropeptide (PMID: 37973885)-nociception-neuroinflammation-research), yet its expression pattern is so different that HK-1 is often described as the "peripheral" or "immune" counterpart to neuronal substance P. For tachykinin researchers, HK-1 fills a conceptual gap that the amphibian and cephalopod reference agonists cannot: a mammalian NK1 ligand whose biology is rooted in the immune system rather than the nervous system.
The tachykinin gene family and where HK-1 fits
Mammalian tachykinins are products of three genes. TAC1 yields [substance P](/learn/substance-p-tachykinin-neuropeptide (PMID: 37973885)-nociception-neuroinflammation-research) and neurokinin A; TAC3 yields neurokinin B; and TAC4 — the most recently discovered — yields hemokinin-1 and the longer endokinins. All share the family's obligatory C-terminal motif Phe-Xaa-Gly-Leu-Met-NH₂, the pharmacophore that drives neurokinin-receptor binding and rapid smooth-muscle contraction. HK-1 was first identified as a hematopoietic-specific tachykinin that regulates B-cell development, a discovery that immediately set it apart from the neuron-derived members of the family Nat Immunol, 2000. The broader TAC4 product set — hemokinins in rodents, endokinins in humans — was subsequently mapped as a coherent subfamily Cell Mol Life Sci, 2004.
| Gene | Principal peptides | Classic source | Receptor preference |
|---|---|---|---|
| TAC1 | Substance P, neurokinin A | Neurons (CNS/sensory) | NK1 (SP), NK2 (NKA) |
| TAC3 | Neurokinin B | Neurons (CNS) | NK3 |
| TAC4 | Hemokinin-1, endokinins | Hematopoietic / immune cells | NK1 |
Structure: an NK1 tachykinin built on the conserved core
Mouse hemokinin-1 is an 11-residue tachykinin terminating in the conserved Phe-Xaa-Gly-Leu-Met-NH₂ amide; in humans the TAC4 transcript is processed into hemokinin-1 together with the endokinins (endokinin A/B and the shorter EKC/EKD), which share the same C-terminal pharmacophore on different N-terminal scaffolds. The gene structures, precursor processing, and resulting pharmacology of the human TAC4 peptides were characterized in detail, establishing how a single gene gives rise to several NK1-active ligands Vascul Pharmacol, 2006. As with the rest of the family, the conserved C-terminus engages the receptor while the variable N-terminus tunes potency and functional behavior — and HK-1's N-terminal domain has been shown to influence functional selectivity at the NK1 receptor, a property of interest for biased-agonism studies Biochem Pharmacol, 2011.
A practical consequence of this gene organization is that "hemokinin-1" in the literature can refer to slightly different molecules depending on species: the rodent peptide is the canonical 11-residue hemokinin-1, while the human TAC4 locus is usually discussed in terms of the endokinins. Researchers selecting a reagent therefore need to match the exact sequence to their model system, since potency and N-terminal-dependent behavior differ across these closely related TAC4 products. This species nuance is one reason HK-1 is best handled as a defined synthetic peptide with a documented sequence rather than assumed equivalent to substance P.
Receptor pharmacology: a non-neuronal NK1 agonist
HK-1 acts at the same NK1 receptor as substance P, and centrally administered hemokinin-1 produces NK1-dependent responses, confirming its identity as a bona fide neurokinin NK1 receptor agonist Neuropharmacology, 2003. Because HK-1 and substance P converge on NK1 yet originate from different cell types and genes, the pair is a natural tool for dissecting where a given NK1 response comes from. Comparative panels built from substance P (neuronal NK1), HK-1 (immune NK1), the amphibian reference physalaemin (NK1), kassinin (NK2), and eledoisin (NK3) let researchers triangulate both receptor subtype and cellular source.
Documented bioactivity in research models
HK-1 displays a tachykinin spectrum centered on immune and sensory biology:
- •B lymphopoiesis. Its founding role was as a regulator of B-cell development; targeted deletion of the TAC4 gene (TAC4⁻/⁻) influences the early stages of B lymphopoiesis, confirming an endogenous function Blood, 2010. HK-1 also exerts a proliferative effect on human B-cells Peptides, 2011.
- •Mast-cell and allergic signaling. Autocrine hemokinin-1 has been reported to function as an endogenous adjuvant for IgE-mediated mast-cell activation, linking the peptide to allergic-type responses in model systems J Allergy Clin Immunol, 2015.
- •Nociceptive models. HK-1 is described as an important mediator of pain in mouse models of neuropathic and inflammatory pain, a research-model readout of its NK1 activity in sensory pathways Brain Res Bull, 2019.
- •Integrative role. A dedicated review summarizes HK-1's documented roles across health-and-disease research models, situating the immune and sensory findings within the wider tachykinin field Neuropeptides, 2017.
These are research findings in defined assay systems, reported only to characterize the reagent's documented experimental behavior — not as functional, therapeutic, or safety claims.
Why hemokinin-1 is a useful research reagent
For tachykinin and neurokinin-receptor researchers, HK-1 offers handles the classic agonists do not:
1. Immune-system NK1 agonist. It probes NK1 biology in hematopoietic and immune contexts rather than neurons Nat Immunol, 2000.
2. Source-discrimination tool. Paired with substance P, it helps separate neuronal from non-neuronal NK1 contributions in mixed tissues.
3. Biased-agonism interest. Its N-terminal domain modulates functional selectivity at NK1 Biochem Pharmacol, 2011.
4. Defined genetics. A cloned TAC4 gene and characterized knockout give a clear loss-of-function reference Blood, 2010.
It pairs naturally with the neuronal NK1 ligand [substance P](/learn/substance-p-tachykinin-neuropeptide (PMID: 37973885)-nociception-neuroinflammation-research), the amphibian NK1 reference physalaemin, the NK2-preferring kassinin, and the NK3-preferring eledoisin in comparative panels, and with vasoactive peptides such as bradykinin for broader smooth-muscle and inflammation studies.
Handling and reconstitution notes
Synthetic hemokinin-1 supplied for research is typically lyophilized and, as a C-terminally amidated tachykinin, is generally water-soluble. Standard practice applies: review the certificate of analysis for identity and purity, confirm purity by HPLC and mass spectrometry, and select a vehicle following a solubility guide. Document reconstitution carefully per standard reconstitution practice, and apply ordinary supplier-evaluation diligence when sourcing material.
Summary
Hemokinin-1 is a mammalian tachykinin encoded by the TAC4 gene, carrying the conserved Phe-Xaa-Gly-Leu-Met-NH₂ motif and acting as an NK1 receptor agonist — but, unlike neuronal substance P, it is produced chiefly in hematopoietic and immune cells. Documented across B lymphopoiesis, mast-cell and allergic signaling, and nociceptive research models, and equipped with defined TAC4 genetics and N-terminal functional-selectivity behavior, HK-1 is the mammalian, non-neuronal NK1 reagent that complements the neuronal substance P and the amphibian/cephalopod reference agonists across the neurokinin receptor subtypes.
Inflammatory disease models and hemokinin-1
The non-neuronal expression of HK-1 has generated significant interest in models of allergic and inflammatory disease. In vivo, HK-1 expression is upregulated in peripheral blood mononuclear cells in atopic dermatitis patients, and in mast cells from murine allergic asthma models, suggesting it contributes to the neurogenic-inflammation component of these conditions via paracrine NK1 activation on adjacent immune and epithelial cells J Neuroinflammation, 2010.
In pain sensitization research, HK-1 has been applied intrathecally and peripherally in rodent models to produce thermal and mechanical hyperalgesia via NK1-mediated dorsal horn sensitization. The hyperalgesia was blocked by NK1-selective antagonists (e.g., aprepitant, L-733,060) but not by NK2/NK3 antagonists, confirming NK1 specificity in these models Biochimie, 2009.
In colitis models, HK-1-positive immune cells are expanded in inflamed colonic mucosa, and exogenous HK-1 application increases inflammatory cytokine production (IL-6, TNF-α) in macrophage cultures at concentrations of 10–100 nM — comparable to the concentrations that activate NK1 in classical smooth-muscle assays. These findings position HK-1 as an immune–neural communication mediator in gut inflammation, distinct from the well-studied neuronal substance P pathway.
HK-1 processing, isoforms, and truncated forms
The TAC4 gene encodes multiple peptides beyond the canonical HK-1. Alternative splicing and precursor processing yield:
- •Hemokinin-1 (full-length): Glu-Pro-Asn-Asn-Pro-Thr-Ala-Ile-Phe-Gly-Leu-Met-NH₂ (12 residues)
- •Endokinin A/B: Longer N-terminally extended forms encoded by different exons of TAC4, with similar C-terminal pharmacophores
- •Endokinin C/D: TAC4-encoded peptides with altered C-termini (not Met-NH₂) that show lower NK1 potency
For research applications, the full-length HK-1 is the most commonly used form. However, truncated N-terminal fragments are used to dissect the biased-agonism properties of the N-terminal domain: HK-1(1-11) lacking the Met amide terminus retains some NK1 binding but with substantially reduced G-protein activation, allowing functional selectivity to be probed at the receptor level Biochem Pharmacol, 2011.
The N-terminal extension unique to HK-1 (compared to substance P) also modulates receptor internalization kinetics — HK-1 produces slower NK1 internalization than substance P at equimolar concentrations in transfected cells, a property relevant to studies examining receptor trafficking, desensitization, and endosomal signaling.
Comparison with substance P in mixed-tissue assays
Because HK-1 and substance P (SP) are both NK1 agonists, distinguishing their respective contributions in mixed tissues (e.g., gut wall, lymph node) requires careful experimental design. Immunohistochemical co-localization studies typically find:
- •SP: present in neurons (enteric, sensory DRG projections), peptidergic nerve fibers
- •HK-1: present in mast cells, B cells, dendritic cells, mucosal epithelium
When both are present, pharmacological tools that help separate their contributions include:
1. Selective NK1 antagonist dose-response: both SP and HK-1 responses are blocked, confirming the receptor but not identifying the source peptide
2. Neurotoxin pre-treatment (capsaicin desensitization): depletes neuronal SP stores while leaving immune-cell HK-1 intact
3. Anti-TAC1 / anti-TAC4 antibody blocking: peptide-specific preabsorption can confirm the source
4. TAC4 knockout tissue: the gold standard for attributing NK1 effects specifically to endogenous HK-1 Blood, 2010
These considerations make HK-1 particularly valuable in studies where neuronal vs. non-neuronal NK1 signaling is the key research question — a growing area in gut-brain axis, neuroimmunology, and chronic pain research.
In vitro assay concentrations and considerations
Ca²⁺ mobilization: In NK1-expressing CHO or HEK cells, HK-1 produces robust Gq-mediated Ca²⁺ transients (EC₅₀ ≈ 0.5–2 nM), comparable to SP. The slightly slower internalization kinetics may result in prolonged Ca²⁺ oscillations relative to SP at the same concentration — a feature worth monitoring in Ca²⁺-imaging experiments with high temporal resolution.
Mast cell degranulation: Primary bone-marrow-derived mast cells (BMMC) or RBL-2H3 cells respond to HK-1 at 10–100 nM with β-hexosaminidase release, histamine secretion, and prostaglandin D₂ production — a validated in vitro readout for immune-NK1 signaling.
B-lymphopoiesis assays: Bone marrow stromal cell co-culture assays with B220⁺ pre-B cell precursors are used to evaluate HK-1's pro-lymphopoietic activity, with dose-response typically measured at 1–100 nM Nat Immunol, 2000.
---
This article is provided for informational and research purposes only. Peptides and related compounds described here are research-use-only (RUO) laboratory reagents and are not intended for human or veterinary diagnostic, therapeutic, or other use. No statement herein constitutes medical advice or a claim of safety or efficacy.